[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655466":3},{"organization":4,"outcomesModule":7,"designInfo":50,"detailedDescription":49,"studyPopulation":53,"armGroups":54,"interventions":60,"overallOfficials":49,"centralContacts":65,"locations":49,"responsibleParty":71,"collaborators":49,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":49,"enrollmentInfo":83,"targetDuration":49,"studyType":86,"phases":49,"briefSummary":87,"conditions":88,"keywords":97,"overallStatus":107,"whyStopped":49,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":49},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":49},[9],{"measure":10,"description":11,"timeFrame":12},"Proportion of participants with death and\u002For organ decompensation at Day 180","Proportion of participants who died and\u002For experienced at least one major comorbidity decompensation (cardiac, renal, or respiratory) by Day 180.","From baseline Day 0 to Day 180",[14,18,21,24,28,32,35,38,42,46],{"measure":15,"description":16,"timeFrame":17},"Proportion of participants who died","Proportion of participants who died from any cause during follow-up.","From baseline Day 0 to Day 30, Day 180, Day 365",{"measure":19,"description":20,"timeFrame":17},"Proportion of participants with major organ decompensation","Proportion of participants experiencing major decompensation of pre-existing comorbidities, including cardiac, renal, or respiratory decompensation.",{"measure":22,"description":23,"timeFrame":17},"Proportion of participants with unplanned hospital readmission","Proportion of participants experiencing an unplanned hospital readmission during follow-up.",{"measure":25,"description":26,"timeFrame":27},"Proportion of participants developing a lower respiratory tract infection","Proportion of participants developing a lower respiratory tract infection (LRTI) following the respiratory viral infection.","From baseline Day 0 to Day 30",{"measure":29,"description":30,"timeFrame":31},"Change from baseline in functional dependency assessed by ADL and\u002For iADL scores","Change in functional dependency from baseline, assessed using the Activities of Daily Living (ADL) and\u002For Instrumental Activities of Daily Living (iADL) scores.","Baseline Day 0, Day 30, Day 180, Day 365",{"measure":33,"description":34,"timeFrame":31},"Change from baseline in sarcopenia risk assessed by SARC-F score","Change in sarcopenia risk from baseline, assessed using the SARC-F score.",{"measure":36,"description":37,"timeFrame":31},"Change from baseline in quality of life assessed by EQ-5D-3L","Change in health-related quality of life from baseline, assessed using the EQ-5D-3L questionnaire.",{"measure":39,"description":40,"timeFrame":41},"Number and type of bacterial and viral co-infections","Number and type of bacterial and viral co-infections diagnosed at the same time as, or within seven days following, the occurrence of the first respiratory viral infection.","Baseline Day 0 to D7",{"measure":43,"description":44,"timeFrame":45},"Change in respiratory viral load between Day 0 and Day 7","Change in viral load between Day 0 and Day 7 for each respiratory virus identified in study participants.","From Day 0 to Day 7",{"measure":47,"description":48,"timeFrame":27},"Proportion of participants with death and\u002For major organ decompensation at Day 30","Proportion of participants who died and\u002For experienced major organ decompensation by Day 30. This outcome will be used to assess vaccine effectiveness for vaccine-preventable respiratory viral infections.",null,{"allocation":49,"interventionModel":49,"interventionModelDescription":49,"primaryPurpose":49,"observationalModel":51,"timePerspective":52,"maskingInfo":49},"COHORT","PROSPECTIVE","Patients aged \\>65 years with a diagnosis of acute respiratory infection and hospitalized in acute\u002Fgeriatric wards",[55],{"label":56,"type":49,"description":57,"interventionNames":58},"Older patients with respiratory viral infection","Patients aged 65 years or older hospitalized in acute medicine or geriatric wards with an acute respiratory infection and a positive nasopharyngeal PCR test for a respiratory viral pathogen.",[59],"Other: Respiratory viral infection",[61],{"type":6,"name":62,"description":63,"armGroupLabels":64,"otherNames":49},"Respiratory viral infection","Respiratory viral infection identified by a positive nasopharyngeal PCR test. The prognostic role of human metapneumovirus (hMPV) infection will be compared with that of other common respiratory viral infections in older hospitalized patients.",[56],[66],{"name":67,"role":68,"phone":69,"phoneExt":49,"email":70},"Giovanna Mrs MELICA, MD, PhD","CONTACT","01 49 81 2455","giovanna.melica@aphp.fr",{"type":72,"investigatorFullName":49,"investigatorTitle":49,"investigatorAffiliation":49,"oldNameTitle":49,"oldOrganization":49},"SPONSOR","100655466","elderly-respiratory-viral-cohort-100655466",false,"NCT07813481","ELderly REspiratory VIral Cohort","Prognostic Role of the Human Metapneumovirus (hMPV) Compared to Other Common Respiratory Viruses in Older Inpatients: a Cohort Study","ELREVI","Inclusion Criteria:\n\n* Patient aged 65 years or older\n* Positive PCR from a nasopharyngeal swab for a respiratory viral pathogen as listed: Influenza A and B, SarsCov2, RSV, hMPV, Rhinovirus\u002FEnterovirus, Adenovirus, Coronavirus (229E, HKU1, NL63, OC43), Parainfluenza Virus 1, 2, 3, 4.\n* Hospitalized in an Acute Medicine\u002FGeriatrics Unit\n* Written informed consent from patient or his\u002Fher representative, with trusted support person, a family member or, failing that, a close friend if the person is physically unable to give his or her written consent. Patients under legal protection (guardianship, curatorship, family authorisation or future protection mandate) may be included with the consent of the legally authorised person.\n* Affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Refusal to participate\n* Patient deprived of liberty by a judicial or administrative decision","ALL","65 Years",{"count":84,"type":85},1000,"ESTIMATED","OBSERVATIONAL","In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and others. HMPV is a respiratory virus discovered in 2001. Like RSV, it appears to be a threat in terms of morbidity and mortality in susceptible populations.\n\nOverall, viral infections can cause significant functional decline in older patients, with 67% and 25% reported to be at least temporarily housebound or bedridden, respectively. Respiratory viral infections prevent older patients from functioning and performing their daily tasks. They therefore have a significant impact on the older patients and their families. In addition, respiratory viruses are key factors in the exacerbation of chronic diseases.\n\nThe aims of this study are to provide a better understanding of the role of hMPV compared to common respiratory viruses on morbimortality, risk of dependency, quality of life alteration in older inpatients.",[89,90,91,92,93,94,95,96],"Influenza Viruses","Respiratory Syncytial Virus (RSV)","Severe Acute Respiratory Syndrome Coronavirus 2","Human Metapneumovirus (hMPV)","Parainfluenza Virus (PIV)","Adenovirus","Rhinovirus","Coronavirus",[98,99,100,101,102,103,104,105,106],"hMPV","RSV","PIV","SarsCov2","respiratory viruses","older adults","prognosis","morbidity","mortality","NOT_YET_RECRUITING","2026-09-04",{"date":110,"type":111},"2026-09-10","ACTUAL",{"date":113,"type":85},"2026-10",{"date":115,"type":85},"2030-10",{"name":5,"class":6}]